Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This emphasizes the importance of considering side effects on the immune system when developing new strategies to specifically target not only MTAP-deficient tumors.
|
31712395 |
2020 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Targeting this redundancy provides a vulnerability for tumors carrying a co-deletion of MTAP and the adjacent CDKN2A tumor suppressor gene.
|
30916320 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The PRMT5 inhibitor EZP015556, shown to target <i>MTAP</i> (a gene commonly lost in pancreatic cancer)-negative tumors, was validated as such, but also appeared to constitute an effective therapy for a subset of MTAP-positive tumors.
|
31818951 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While the lack of the methionine salvage enzyme methylthioadenosine phosphorylase (MTAP) is associated with methionine auxotrophy in cancer cells, there are other causes for tumors to require exogenous methionine.
|
30725403 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A decrease in MTAP expression was observed in RCC tissues and correlated with higher tumor grade and shorter overall survival.
|
30701095 |
2019 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
It was demonstrated that in these tumors BRAF V600E mutated and that CDKN2A/B MTAP co-deletions may be used for stratifying patients for a stricter surveillance.
|
30558563 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Methylthioadenosine phosphorylase (MTAP) deficiency has been recently associated with increased tumor aggressiveness and poor outcomes in different types of neoplasms.
|
29243509 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results suggest that 2FA+MTA may be a promising combination for treating <i>MTAP</i>-deleted tumors.<b>Significance:</b> Loss of MTAP occurs in about 15% of all human cancers; the MTAP protection strategy presented in this study could be very effective in treating these cancers.<i></i>.
|
29844120 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
While the lack of the methionine salvage enzyme methylthioadenosine phosphorylase (MTAP) deficiency is associated with methionine dependence in cancer cells, there are other causes for tumors to require exogenous methionine.
|
29733806 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MTAP has a tumor suppressor activity and epigenetic silencing has been described in melanoma cell lines.
|
27761950 |
2017 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MTAP expression was also evaluated in two groups of samples from breast cancer patients, fresh tumors and paired normal breast tissue, and from formalin-fixed paraffin embedded (FFPE) core breast cancer samples diagnosed as Luminal-A tumors and triple negative breast tumors (TNBC).
|
26751376 |
2016 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Intriguingly, five CPGs showed concordance between CNL and down-regulation in 50 or more tumor samples: MTAP (216 samples), PTEN (143), MCPH1 (86), SMAD4 (63), and MINPP1 (51), which may represent the recurrent driving force for gene expression change during oncogenesis.
|
27929028 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Methylthioadenosine phosphorylase (MTAP) and the tumor suppressor genes CDKN2A-CDKN2B are frequently deleted in malignancies.
|
26872600 |
2016 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We also detected fusion transcripts involving MTAP and ANRIL in two of the seven primary melanoma tumors with focal deletion at the locus.
|
26909863 |
2016 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Enzyme assays conducted on the co-dominantly expressed alleles revealed no difference in the conversion rate of MTA to adenine and 5-methylthioribose-1-phosphate, indicating that this known enzymatic activity does not modulate the tumor suppressive function of MTAP.
|
27479139 |
2016 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In methylthioadenosine phosphorylase (MTAP)-deficient glioblastoma cells, expression of MTAP transgene did not alter methionine dependency, but compromised tumor growth in vivo We discovered that a lack of the kynurenine-metabolizing enzymes kynurenine monooxygenase and/or kynureninase promotes the accumulation of kynurenine, which triggers immune evasion in glioblastoma cells.
|
26936918 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
MTAP is frequently lost due to its proximity to the commonly deleted tumor suppressor gene, CDKN2A.
|
26912360 |
2016 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The MTAP gene is frequently deleted in human cancers because of its chromosomal proximity to the tumor suppressor gene CDKN2A.
|
26912361 |
2016 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Copy number losses and homozygous deletions at the chromosome 9p region affecting the CDKN2A and MTAP genes were the most frequent alterations in both groups of tumors.
|
26235493 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Loss of methylthioadenosine phosphorylase (MTAP) expression and a concomitant accumulation of 5'-methyl-thioadenosine (MTA) characterise several tumour entities including malignant melanoma.
|
23265702 |
2013 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This gene region houses the CDKN2B/p15(INK4B) , CDKN2A/p16(INK4A) and p14ARF (rat equivalent, p19(ARF) ) tumour suppressor genes and is adjacent to the S-methyl-5'-thioadenosine phosphorylase (MTAP) gene.
|
24069379 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The gene encoding the methionine salvage pathway methylthioadenosine phosphorylase (MTAP) is a tumor suppressor gene that is frequently inactivated in a wide variety of human cancers.
|
23840755 |
2013 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This therapeutic approach can be applied to other MTAP-deficient human cancers as deletion or hypermethylation of the MTAP gene occurs in a broad spectrum of tumors at high frequency.
|
22252602 |
2012 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The tumor suppressor genes CDKN2A and MTAP were each homozygously deleted in four of the cases, and the RB1 gene was homozygously deleted in one.
|
23146407 |
2012 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Low MTAP mRNA expression was found in 32% of cases, and was associated with MTAP gene deletion (in 70%; P<0.001) but not with MTAP promoter hypermethylation, indicating that, in this tumour, gene deletion is the main mechanism for MTAP inactivation.
|
23020581 |
2012 |